samedan logo
 
 
 
spacer
home > ebr > summer 2018 > engineering antibodies
PUBLICATIONS
European Biopharmaceutical Review

Engineering Antibodies

Antibody-drug conjugates (ADCs) are a novel class of treatment agents that combine the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. Compared to chemotherapy, ADCs have a more favourable therapeutic index. As of today, four ADCs have been approved. However, development is still ongoing to improve the therapeutic window of ADCs further and to expand their landscape of targets and toxic payloads. The challenges of ADCs and the strategies pursued to overcome these are described. During their evolution, three generations of ADCs can be distinguished, each overcoming certain limitations.

ADCs combine the target specificity of monoclonal antibodies and the high efficacy of a cytotoxic compound. Each of the components has its limitations: lack of direct pharmacological effect of antibodies and no selectivity of the toxic effect of a chemotherapeutic for cancer cells. The promise of ADCs has been to make use of the advantages of both components and to get rid of the limitations.

The Beginning of ADCs

The ADC era began in 1993 with BR96 doxorubicin − a monoclonal antibody linked to approximately eight doxorubicin molecules, which is directed against the Lewis-Y antigen. The clinical development was stopped due to poor clinical responses. Mylotarg was the only first generation of ADC being approved by the FDA in 2000 for use in patients over the age of 60 with relapsed acute myelogenous leukemia. However, its medical use was limited by severe side effects. Within the first year after approval, the FDA required a black box warning be added to packaging. Despite attempts to resolve this, in June 2010 Mylotarg was withdrawn from the market at the request of the FDA. Notably, it was reapproved in July 2017 using dose fractionation to circumvent side effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Andreas Pahl has served as Chief Scientific Officer of Heidelberg Pharma since June 2016 and Chief Scientific Officer of Heidelberg Pharma Research since September 2012. Prior to his position at Heidelberg Pharma, he was Head of Late Pharmacology at Nycomed and Takeda Pharmaceuticals. After graduating in chemistry from the University of Berlin, Germany, he spent several years lecturing at TU Berlin and the University of Erlangen-Nuremberg FAU, at which he was also appointed Professor of Pharmacology and Toxicology. He still performs his teaching duties at FAU.
spacer
Professor Andreas Pahl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cognizant Shared Investigator Platform for Life Sciences Reaches Major Milestone in Accelerating Drug Discovery

Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries. The platform has become increasingly critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement